Editor, – We read Associate Professor Shephard's article with interest (Aust Prescr 2010;33:6–9), and wish to highlight emerging uses for point-of-care INR monitors in Australia. These have been trialled in various settings including:
- rural general practices1and community pharmacies2, to improve warfarin safety in patients with limited access to pathology services
- patients' homes, to facilitate self-monitoring via a standardised training program3*and as a part of a multi-faceted post-discharge service provided by home medicines review accredited pharmacists4*
- within residential care facilities.5
These projects, conducted by the Unit for Medication Outcomes Research and Education (UMORE), have improved patient outcomes and produced excellent stakeholder satisfaction. For example, the post-discharge service was recently associated with reduced rates of warfarin-related adverse events up to 90 days post-discharge.4
Patient self-monitoring is well established in Europe, where it is associated with improved anticoagulation control, enhanced patient convenience and adherence, fewer complications and improved survival in suitable patients.6Currently, only a small proportion of Australian patients taking warfarin perform self-monitoring, a situation that could be improved by a national training, quality assurance and support program.
We believe that appropriate use of point-of-care INR monitors outside traditional settings can potentially improve patients' quality of life and health outcomes and, as such, should be actively promoted and government-funded.
Gregory Peterson, Leanne Stafford, Luke Bereznicki, Ella van Tienen and Shane Jackson
Unit for Medication Outcomes Research and Education
(UMORE), School of Pharmacy
University of Tasmania
*These programs were funded by the Department of Health and Ageing as part of the Fourth Community Pharmacy Agreement managed by the Pharmacy Guild of Australia